Format
A data frame with 198 observations on the following 3 variables.
study
- a factor with levels
I
, II
,
III
, and IV
describing the study number. treatment
- a factor with levels
Misoprostol
Placebo
classification
- an ordered factor with levels
1
< 2
< 3
< 4
< 5
describing an ordered response variable.
Source
F. L. Lanza (1987), A double-blind study of prophylactic effect of misoprostol on
lesions of gastric and duodenal mucosa induced by oral administration of tolmetin
in healthy subjects. British Journal of Clinical Practice, May
suppl, 91--101. F. L. Lanza, R. L. Aspinall, E. A. Swabb, R. E. Davis, M. F. Rack, A. Rubin
(1988a), Double-blind, placebo-controlled endoscopic comparison of the
mucosal protective effects of misoprostol versus cimetidine on
tolmetin-induced mucosal injury to the stomach and duodenum.
Gastroenterology, 95(2), 289--294. F. L. Lanza, K. Peace, L. Gustitus, M. F. Rack, B. Dickson (1988b),
A blinded endoscopic comparative study of misoprostol versus
sucralfate and placebo in the prevention of aspirin-induced
gastric and duodenal ulceration. American Journal of Gastroenterology,
83(2), 143--146. F. L. Lanza, D. Fakouhi, A. Rubin, R. E. Davis, M. F. Rack, C. Nissen, S. Geis
(1989), A double-blind placebo-controlled comparison of the efficacy
and safety of 50, 100, and 200 micrograms of misoprostol
QID in the prevention of ibuprofen-induced gastric and
duodenal mucosal lesions and symptoms. American Journal of Gastroenterology,
84(6), 633--636.